...
首页> 外文期刊>Science Advances >Nanoparticles that do not adhere to mucus provide uniform and long-lasting drug delivery to airways following inhalation
【24h】

Nanoparticles that do not adhere to mucus provide uniform and long-lasting drug delivery to airways following inhalation

机译:不会粘在粘液上的纳米颗粒可在吸入后向气道提供均匀且持久的药物输送

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Mucoadhesive particles (MAP) have been widely explored for pulmonary drug delivery because of their perceived benefits in improving particle residence in the lungs. However, retention of particles adhesively trapped in airway mucus may be limited by physiologic mucus clearance mechanisms. In contrast, particles that avoid mucoadhesion and have diameters smaller than mucus mesh spacings rapidly penetrate mucus layers [mucus-penetrating particles (MPP)], which we hypothesized would provide prolonged lung retention compared to MAP. We compared in vivo behaviors of variously sized, polystyrene-based MAP and MPP in the lungs following inhalation. MAP, regardless of particle size, were aggregated and poorly distributed throughout the airways, leading to rapid clearance from the lungs. Conversely, MPP as large as 300 nm exhibited uniform distribution and markedly enhanced retention compared to size-matched MAP. On the basis of these findings, we formulated biodegradable MPP (b-MPP) with an average diameter of <300 nm and examined their behavior following inhalation relative to similarly sized biodegradable MAP (b-MAP). Although b-MPP diffused rapidly through human airway mucus ex vivo, b-MAP did not. Rapid b-MPP movements in mucus ex vivo correlated to a more uniform distribution within the airways and enhanced lung retention time as compared to b-MAP. Furthermore, inhalation of b-MPP loaded with dexamethasone sodium phosphate (DP) significantly reduced inflammation in a mouse model of acute lung inflammation compared to both carrier-free DP and DP-loaded MAP. These studies provide a careful head-to-head comparison of MAP versus MPP following inhalation and challenge a long-standing dogma that favored the use of MAP for pulmonary drug delivery.
机译:粘膜粘附性颗粒(MAP)已被广泛地用于肺部药物的输送,因为它们具有改善颗粒在肺中的滞留性的好处。然而,粘附在气道粘液中的颗粒的保留可能受到生理粘液清除机制的限制。相反,避免粘膜粘连并且直径小于粘液网格间距的颗粒会迅速渗透粘液层[粘液穿透颗粒(MPP)],我们认为,与MAP相比,粘液可延长肺的滞留时间。我们比较了吸入后肺中各种大小的基于聚苯乙烯的MAP和MPP的体内行为。 MAP,无论颗粒大小如何,均会聚集并在整个气道中分布不均,导致迅速从肺中清除。相反,与尺寸匹配的MAP相比,高达300 nm的MPP表现出均匀的分布并显着提高了保留率。基于这些发现,我们配制了平均直径小于300 nm的可生物降解的MPP(b-MPP),并检查了吸入后相对于类似尺寸的可生物降解的MAP(b-MAP)的行为。尽管b-MPP在体外从人气道粘液中迅速扩散,但b-MAP没有。与b-MAP相比,离体粘液中b-MPP的快速运动与气道内更均匀的分布和增加的肺滞留时间相关。此外,与不含载体的DP和含DP的MAP相比,吸入含地塞米松磷酸钠(DP)的b-MPP可以显着减少急性肺部炎症小鼠模型的炎症。这些研究提供了吸入后MAP与MPP的仔细头对头比较,并挑战了长期存在的教条,该教条赞成使用MAP进行肺部药物递送。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号